Literature DB >> 17474812

Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia.

Gunnar Morken1, Rolf W Grawe, Jan H Widen.   

Abstract

OBJECTIVE: Interventions improving adherence to antipsychotic medication are needed. The present study examined the effects on medication adherence of 2 years of integrated treatment for patients with schizophrenia.
METHOD: Adherence to medication was examined in a randomized controlled trial of 2 years of integrated treatment versus standard treatment. The 50 included patients were consecutively referred to a specialized psychiatric team for treatment of psychosis and were diagnosed with DSM-IV schizophrenia or schizoaffective or schizophreniform disorder. The patients were clinically stable and had less than 2 years' duration of illness. Integrated treatment consisted of assertive outreach community treatment, family psychoeducation and involvement, and social skills training. Good adherence was defined as less than 1 month without medication. Outcomes were compared over 12-month and 24-month follow-up periods. The study was conducted from February 1992 to October 1999.
RESULTS: No difference in adherence between the integrated treatment group and the standard treatment group (chi(2) = 0.06, NS) was found. Men were more nonadherent than women (OR 6.11 [CI 1.25 to 29.74], p = .025). Patients living in families with low expressed emotion were less adherent than patients living in families with high expressed emotion (OR 6.04 [CI 1.07 to 34.13], p = .042).
CONCLUSION: No effects of integrated treatment on medication adherence were found. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00184509.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17474812     DOI: 10.4088/jcp.v68n0409

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

Review 1.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Ethical considerations when treating patients with schizophrenia.

Authors:  Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2008-04

Review 3.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Hanna Bergman; Mariam A Khokhar; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2017-01-06

Review 4.  Schizophrenia.

Authors:  Sarah Je Barry; Tracey M Gaughan; Robert Hunter
Journal:  BMJ Clin Evid       Date:  2012-06-28

5.  Specialised early intervention teams for recent-onset psychosis.

Authors:  Stephen Puntis; Amedeo Minichino; Franco De Crescenzo; Andrea Cipriani; Belinda Lennox; Rachael Harrison
Journal:  Cochrane Database Syst Rev       Date:  2020-11-02

6.  Specialised early intervention teams (extended time) for recent-onset psychosis.

Authors:  Stephen Puntis; Amedeo Minichino; Franco De Crescenzo; Andrea Cipriani; Belinda Lennox; Rachael Harrison
Journal:  Cochrane Database Syst Rev       Date:  2020-11-02

Review 7.  Strategies to improve medication adherence in patients with schizophrenia: the role of support services.

Authors:  Peggy El-Mallakh; Jan Findlay
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-16       Impact factor: 2.570

8.  The development and trial of a medication discontinuation program in the department of forensic psychiatry.

Authors:  Kenji Murasugi; Teruomi Tsukahara; Shinsuke Washizuka
Journal:  Ann Gen Psychiatry       Date:  2015-02-27       Impact factor: 3.455

9.  Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.

Authors:  Gunnar Morken; Jan H Widen; Rolf W Grawe
Journal:  BMC Psychiatry       Date:  2008-04-30       Impact factor: 3.630

10.  Integrated treatment vs. treatment-as-usual for recent onset schizophrenia; 12 year follow-up on a randomized controlled trial.

Authors:  Víðir Sigrúnarson; Rolf W Gråwe; Gunnar Morken
Journal:  BMC Psychiatry       Date:  2013-07-30       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.